Phenotype switching in melanoma: implications for progression and therapy

Area of Science:

• Oncology
• Molecular Biology
• Dermatology

Background:

• Epithelial-mesenchymal transition (EMT) drives cancer metastasis.
• Melanoma exhibits EMT-like phenotype switching, linked to metastatic progression.
• BRAF inhibitors are effective but face resistance, leading to disease progression.

Purpose of the Study:

• To review research on EMT-like processes in melanoma.
• To explore signaling pathways and transcription factors regulating melanoma EMT.
• To associate these processes with therapy response, particularly BRAF inhibition resistance.

Main Methods:

• Literature review of recent research on melanoma EMT.
• Analysis of studies on receptor tyrosine kinases (RTKs) in melanoma progression.
• Examination of mechanisms underlying BRAF inhibitor resistance and phenotype switching.

Main Results:

• EMT-like processes and specific RTKs promote melanoma proliferation, invasion, and metastasis.
• Melanoma phenotype switching is implicated in resistance to BRAF inhibition.
• Insights into these mechanisms can predict melanoma progression during treatment.

Conclusions:

• Understanding EMT-like processes is crucial for predicting melanoma progression.
• Targeting EMT pathways may overcome BRAF inhibitor resistance.
• This knowledge can guide the development of effective combination therapies for melanoma.